Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM6B | O15054 | 1/20 | 0.56 |
| ▸ | KDM4A | O75164 | 1/20 | 0.56 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.56 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.56 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3577936 | 0.78 | KDM6B (0.58) | KDM6BKDM4AKDM4DHIF1ANKDM2A | |
| SCHEMBL19725083 | 0.76 | KDM6B (0.56) | KDM6BKDM4AKDM4DHIF1ANKDM2A | |
| SCHEMBL2713726 | 0.76 | KDM6B (0.56) | KDM6BKDM4AKDM4DHIF1ANKDM2A | |
| SCHEMBL16466339 | 0.76 | KDM6B (0.56) | KDM6BKDM4AKDM4DHIF1ANKDM2A | |
| SCHEMBL13525026 | 0.76 | KDM6B (0.61) | KDM6BKDM4AKDM4DHIF1ANKDM2A | |
| SCHEMBL14616426 | 0.74 | — | — | |
| SCHEMBL18689737 | 0.73 | KDM6B (0.53) | KDM6BKDM4AKDM4DHIF1ANKDM2A | |
| SCHEMBL11900387 | 0.73 | LMNA (0.59) | KDM6BKDM4AKDM4DHIF1ANKDM2A | |
| SCHEMBL2027355 | 0.72 | MAPK1 (0.69) | KDM6BKDM4AKDM4DHIF1ANKDM2A | |
| SCHEMBL4766387 | 0.72 | KDM6B (1.00) | KDM6BKDM4AKDM4DHIF1ANKDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-119768164-A | Pharmaceutical compounds for treating complement-mediated disorders | 阿雷克森制药公司 | 2025-04-04 | — | — | CN | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| US-9006433-B2 | Substituted pyrimidines | MERCK SHARP & DOHME CORP. (US) | 2015-04-14 | — | — | US | disclosed |
| US-8450343-B2 | Gamma secretase modulators | SCHERING CORPORATION | 2013-05-28 | — | — | US | disclosed |
| US-8450343-B2 | Gamma secretase modulators | SCHERING CORPORATION | 2013-05-28 | — | — | US | disclosed |
| US-20130018053-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME LLC | 2013-01-17 | — | — | US | disclosed |
| EP-2522670-A1 | Heterocyclic CRF receptor antagonists | Takeda Pharmaceutical Company Limited (JP) | 2012-11-14 | — | — | EP | disclosed |
| WO-2011130908-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME CORP. (US) | 2011-10-27 | — | — | WO | disclosed |
| US-7897607-B2 | Cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-01 | — | — | US | disclosed |
| WO-2008079291-A2 | SUBSTITUTED HETEROCYCLES AND METHODS OF USE | AMGEN INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079291-A2 | SUBSTITUTED HETEROCYCLES AND METHODS OF USE | AMGEN INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| EP-1732541-A4 | CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2008-03-05 | — | — | EP | disclosed |
| US-20070179165-A1 | Cyclic compounds | GYORKOS ALBERT C | 2007-08-02 | — | — | US | disclosed |
| US-7217794-B2 | Compounds and methods for treatment of thrombosis | DAIAMED, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| EP-1732541-A2 | CYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005099688-A2 | CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-10-27 | — | — | WO | disclosed |
| US-20050143317-A1 | Compounds and methods for treatment of thrombosis | EXITHERA PHARMACEUTICALS LLC | 2005-06-30 | — | — | US | disclosed |
| WO-2004103270-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF THROMBOSIS | SUNTORY PHARMACEUTICAL RESEARCH LABORATORIES LLC (US) | 2004-12-02 | — | — | WO | disclosed |
| WO-2004089297-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF THROMBOSIS | SUNTORY PHARMACEUTICAL RESEARCH LABORATORIES, LLC (US) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018053-A1 | SUBSTITUTED PYRIMIDINES | HIF1AN, HIF1A, EGLN3 | KDM6B 362/4885KDM4A 278/4885KDM4D 534/4885 |
| US-20050143317-A1 | Compounds and methods for treatment of thrombosis | SERPINC1, F11, F13B | KDM6B 1350/4885KDM4A 1920/4885KDM4D 1498/4885 |
| US-20070179165-A1 | Cyclic compounds | CRHR1, CRHR2, MC2R | KDM6B 2289/4885KDM4A 2957/4885KDM4D 3606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.